Nicotinamide and 5-ASA Combination for Intestinal Microbiota Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases associated with changes in intestinal microbiota and impaired interactions between the intestinal microbiota and the intestines lack effective methods to beneficially influence the microbiota, leading to inadequate management of associated diseases such as inflammatory bowel diseases, atopic conditions, and metabolic disorders.
Innovation Solution
A pharmaceutical composition combining nicotinamide or related compounds with 5-aminosalicylic acid (5-ASA) is selectively released in the small intestine and colon, influencing the intestinal microbiota to reduce inflammation and promote a healthy balance, thereby treating and preventing inflammatory diseases and conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for inflammatory bowel diseases are used, then existing therapeutic options are available, but they lack effective methods to beneficially influence the intestinal microbiota
Solution Approach 1:
The patent combines nicotinamide and 5-ASA into a single pharmaceutical composition, merging two therapeutic agents with complementary mechanisms of action. Nicotinamide addresses microbiota-related inflammation while 5-ASA provides established anti-inflammatory effects, creating a synergistic treatment that simultaneously targets multiple pathological pathways in IBD
Solution Approach 2:
The pharmaceutical composition serves multiple functions: it treats existing inflammation, beneficially influences intestinal microbiota composition, prevents disease relapses, and reduces risk of colon carcinoma. This multi-functional approach allows a single formulation to address various aspects of IBD pathology that previously required separate treatments
2Reliability
If single-agent therapies are used, then treatment simplicity is maintained, but anti-inflammatory efficacy is insufficient
Solution Approach 1:
The patent integrates nicotinamide and 5-ASA into a single combined pharmaceutical composition, allowing simultaneous administration of two active agents with complementary anti-inflammatory mechanisms. This merger enhances therapeutic efficacy while maintaining treatment simplicity through a single formulation rather than requiring multiple separate medications
3Quantity of substance
If systemic administration is used, then broad coverage is achieved, but local concentration at the intestinal mucosa is reduced
Solution Approach 1:
The pharmaceutical composition is designed for localized action at the intestinal mucosa and microbiota interface. By targeting the specific site of pathology in the gastrointestinal tract, the treatment achieves high local concentration of both nicotinamide and 5-ASA where needed, while minimizing systemic circulation and associated side effects
Data Source
AI summary
The present invention relates to a new pharmaceutical composition containing a combination of 5-aminosalicylic acid and nicotinamide or related compounds. The combination is believed to beneficially influence the intestinal microbiota and/or reduce gastrointestinal inflammation. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.